drugset / Trial / NCT01148966
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors. Aminolevulinic acid becomes active when it is exposed to a certain kind of light and may help doctors find and remove tumor cells during surgery
Timeline
- Start
- 2010-06
- Primary completion
- 2012-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 10 mg/kg | Oral |
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 20 mg/kg | Oral |
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 30 mg/kg | Oral |